Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about IgE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| Tralokinumab | downregulates | drug | 0.85 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Epigenetic clocks association with brain aging patterns in older women | exploratory | cognitive impairment and demen | 0.900 | 0.00 | human patients | proposed | N/A |
| Tet2 modulation in Aβ42-injured mouse hippocampal neurons | exploratory | Alzheimer's disease | 0.900 | 0.00 | primary mouse hippocampal neur | proposed | N/A |
| AAV-mediated Tet2 modulation in 2×Tg-AD mice behavioral study | validation | Alzheimer's disease | 0.900 | 0.00 | young APPswe/PSEN1 double-tran | proposed | N/A |
| Gandouling protection against brain injury in Wilson's disease via SIR | validation | Hepatolenticular degeneration | 0.900 | 0.00 | TX mice (Wilson's disease mode | proposed | N/A |
| Tet2 expression analysis in aged 2×Tg-AD mouse brains | exploratory | Alzheimer's disease | 0.850 | 0.00 | APPswe/PSEN1 double-transgenic | proposed | N/A |
| Proposed experiment from debate on Epigenetic clocks and biological ag | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | completed | $450,000 |
| CRISPR Gene Correction Approaches for CBS/PSP | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Proposed experiment from debate on Epigenetic clocks and biological ag | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Epigenetic Dysregulation in Huntington's Disease — Therapeutic Targeti | validation | Neurodegeneration | 0.400 | 0.50 | human | completed | $3,000,000 |
| Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disea | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Exercise-BDNF-Mitophagy Biomarker Study in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Lifestyle Intervention Mechanisms in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $430,000 |
| MLCS Quantification in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Sirtuin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Sirtuin Pathway Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Cognitive Reserve Mechanisms in Alzheimer's Disease — Molecular Basis | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | completed | $6,550,000 |
| Epigenetic Clocks in Neurodegeneration — Causal Drivers or Passive Mar | validation | Neurodegeneration | 0.400 | 0.50 | human | completed | $3,000,000 |
| Epigenetic Dysregulation Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Normal Aging to Alzheimer's Disease Transition Trigger — Identifying t | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Clonal Hematopoiesis in Nonmalignant Disease: Functional Consequences of Mutated [PMID:40929507] | Koh Y, Tengesdal IW, Jaiswal S | Annu Rev Pathol | 2026 | 1 |
| TET2 guards against unchecked BATF3-induced CAR T cell expansion. [PMID:36755094] | Jain N, Zhao Z, Feucht J, Koche R, Iyer | Nature | 2023 | 1 |
| Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Futur [PMID:36928826] | Singh I, Singh A | Curr Oncol Rep | 2023 | 1 |
| The function and regulation of TET2 in innate immunity and inflammation. [PMID:33085059] | Cong B, Zhang Q, Cao X | Protein Cell | 2021 | 1 |
| Global epigenomic reconfiguration during mammalian brain development. [PMID:23828890] | Lister R, Mukamel EA, Nery JR, Urich M, | Science | 2013 | 1 |
| TET1 deficiency amplifies macrophage inflammatory signaling associated with Croh [PMID:41896302] | ["Perez R", "Paul R", "Kumar P", "Tutkun | Inflammation research : offici | 2026 | 0 |
| NAD+ subcellular partitioning mediated by miR-183 and miR-96 regulates muscle st [PMID:41915008] | Ma M, Ma R, Li Z, Shen S, Kong W, Qiu T, | Journal of molecular cell biol | 2026 | 0 |
| Tet methylcytosine dioxygenase 2(TET2)-dependent epigenetic regulation in the pa [PMID:41811389] | Liu K, Hong Y, Gao Q, Huang J, Liu L, Li | Cellular and molecular life sc | 2026 | 0 |
| Clonal Hematopoiesis in Cardiovascular Risk: Focus on Inflammatory Mechanisms. [PMID:41899316] | ["Sinnadurai S", "Honigberg M", "Meijers | Journal of clinical medicine | 2026 | 0 |
| Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects. [PMID:41926089] | Park CS, Ryu G, Ahn HJ, Sun C, Lee SP, K | JAMA oncology | 2026 | 0 |
| Rhodiola sacra Protects Against Hippocampal Neuronal Apoptosis in Chronic Cerebr [PMID:41879438] | Zhou L, Jia J, Li J, Yao Z, Fu Z, Wang S | Current neuropharmacology | 2026 | 0 |
| Mechanistic Modulation of Autophagy by Bioactive Natural Products: Implications [PMID:41830033] | Jalouli M, Harrath AH, Al-Zharani M, Rah | Nutrients | 2026 | 0 |
| Chimeric antigen receptor T-cell therapies related to immune effector cell-assoc [PMID:41914034] | Zhang Y, Yang J, Xin H, Ai K, Yang M, Li | Chinese medical journal | 2026 | 0 |
| Epigenetic mechanisms and therapeutic innovations in chronic pain-associated neu [PMID:41554641] | Zhang K, Zhu S, Xing N, Zhou Z, Chen J e | Br J Pharmacol | 2026 | 0 |
| Mechanistic advances in exercise‑mediated regulation of autophagy dysfunction in [PMID:41645754] | Li W, Wang WH, Song Y, Li XJ, Li Y et al | Int J Mol Med | 2026 | 0 |
| Homoplantaginin ameliorates osteoarthritis by activating Sirt3/PINK1/Parkin sign [PMID:41720004] | Zhang H, Xiao J, Yi Y, Chen B, Lv W et a | Phytomedicine | 2026 | 0 |
| Kakkalide promotes spinal cord injury repair by regulating microglial M2 polariz [PMID:41720005] | You T, Dai B, Ding X, He Z, Peng J et al | Phytomedicine | 2026 | 0 |
| Histone deacetylases: Function in tumor development and therapeutic prospects (R [PMID:41783166] | Lin R, Zhang Y, Li H, Liang F | Oncol Lett | 2026 | 0 |
| Fibroblast histone deacetylase-1 promotes kidney interstitial fibrosis following [PMID:41830491] | Nguyen H, Mendoza LD, Oliver AS, Aldaz K | Am J Physiol Renal Physiol | 2026 | 0 |
| Integrative SMR prioritizes oxidative stress-related regulatory genes for Alzhei [PMID:41844011] | Wu L, Dong YT, Mu X, Luo X, Chen ZJ | J Prev Alzheimers Dis | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning IgE in their description or question text
Score: 0.701 · neurodegeneration · 2026-04-02
## Mechanistic Overview Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration starts from the claim that modulating SI
Score: 0.700 · neurodegeneration · 2026-04-22
## **Molecular Mechanism and Rationale** The molecular foundation of this hypothesis centers on the intricate relations
Score: 0.670 · neurodegeneration · 2026-04-02
## Mechanistic Overview Nutrient-Sensing Epigenetic Circuit Reactivation starts from the claim that modulating SIRT1 wit
Score: 0.661 · metabolic neuroscience · 2026-04-16
## Mechanistic Overview Epigenetic Priming Ketone Protocol starts from the claim that modulating HDAC2/HDAC3 within the
Score: 0.650 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The molecular foundation of this therapeutic approach centers on the dual functio
Score: 0.650 · neurodegeneration · 2026-04-22
## Mechanistic Overview Loss of Homeostatic Epigenetic Identity Reprograms Microglia to Dystrophic State starts from the
Score: 0.647 · Alzheimer's disease · 2026-04-04
## Mechanistic Overview Epigenetic Reprogramming of Microglial Memory starts from the claim that modulating DNMT3A, HDAC
Score: 0.643 · neuroinflammation · 2026-04-21
## **Molecular Mechanism and Rationale** The epigenetic silencing of the AIF1 (Allograft Inflammatory Factor 1) gene lo
Score: 0.630 · neurodegeneration · 2026-04-02
## Mechanistic Overview FOXO3-Longevity Pathway Epigenetic Reprogramming starts from the claim that modulating FOXO3 wit
Score: 0.630 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** Partial OSK reprogramming operates through the controlled expression of three Yam
Score: 0.630 · neurodegeneration · 2026-04-22
## Mechanistic Overview Epigenetic Bivalency at CDKN2A Locus Distinguishes Senescent from Activated Microglia starts fro
Score: 0.630 · neurodegeneration · 2026-04-02
## Mechanistic Overview Programmable Neuronal Circuit Repair via Epigenetic CRISPR starts from the claim that modulating
Score: 0.626 · neurodegeneration · 2026-04-28
PD genetic aging variants accelerating cell-type-specific epigenetic clock trajectories should produce a measurable prox
Score: 0.620 · neurodegeneration · 2026-04-25
The Senescence-Associated Epigenetic Phenotype (SEP) is hypothesized to contribute to neurodegeneration, potentially act
Score: 0.612 · neurodegeneration · 2026-04-28
The question is likely underpowered or misleading unless analyses preserve the key strata: PD-. Averaging across these s